Nucleophosmin supports WNT-driven hyperproliferation and tumor initiation.

Saved in:
Bibliographic Details
Title: Nucleophosmin supports WNT-driven hyperproliferation and tumor initiation.
Authors: Kanellos G; Cancer Research UK Scotland Institute, Glasgow, UK. g.kanellos@crukscotlandinstitute.ac.uk., Giacomelli C; Cancer Research UK Scotland Institute, Glasgow, UK., Raven A; Cancer Research UK Scotland Institute, Glasgow, UK., Vlahov N; Cancer Research UK Scotland Institute, Glasgow, UK., Jin H; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Herviou P; Cancer Research UK Scotland Institute, Glasgow, UK., Malla SB; Cancer Research UK Scotland Institute, Glasgow, UK.; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK., Nasreddin N; Cancer Research UK Scotland Institute, Glasgow, UK., Centeno PP; Cancer Research UK Scotland Institute, Glasgow, UK., Alexandrou C; Cancer Research UK Scotland Institute, Glasgow, UK., Gilroy K; Cancer Research UK Scotland Institute, Glasgow, UK., Baird RL; Cancer Research UK Scotland Institute, Glasgow, UK., Pennel K; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Munro J; Cancer Research UK Scotland Institute, Glasgow, UK., Waldron JA; Cancer Research UK Scotland Institute, Glasgow, UK., Hall H; Cancer Research UK Scotland Institute, Glasgow, UK., Officer-Jones L; Cancer Research UK Scotland Institute, Glasgow, UK., Bryson S; Cancer Research UK Scotland Institute, Glasgow, UK., Strathdee D; Cancer Research UK Scotland Institute, Glasgow, UK., Lilla S; Cancer Research UK Scotland Institute, Glasgow, UK., Zanivan S; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Morrison V; Cancer Research UK Scotland Institute, Glasgow, UK., Nixon C; Cancer Research UK Scotland Institute, Glasgow, UK., Ridgway RA; Cancer Research UK Scotland Institute, Glasgow, UK., Miller C; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Knight JRP; Cancer Research UK Scotland Institute, Glasgow, UK.; Division of Cancer Sciences, University of Manchester, Manchester, UK., Campbell AD; Cancer Research UK Scotland Institute, Glasgow, UK., Dunne PD; Cancer Research UK Scotland Institute, Glasgow, UK.; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK., Le Quesne J; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; Department of Histopathology, Queen Elizabeth University Hospital, Glasgow, UK., Edwards J; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Park PJ; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Bushell M; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Sansom OJ; Cancer Research UK Scotland Institute, Glasgow, UK. o.sansom@crukscotlandinstitute.ac.uk.; School of Cancer Sciences, University of Glasgow, Glasgow, UK. o.sansom@crukscotlandinstitute.ac.uk.
Source: Nature genetics [Nat Genet] 2026 Jan; Vol. 58 (1), pp. 100-115. Date of Electronic Publication: 2025 Dec 18.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Co Country of Publication: United States NLM ID: 9216904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-1718 (Electronic) Linking ISSN: 10614036 NLM ISO Abbreviation: Nat Genet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-1718
DOI:10.1038/s41588-025-02408-7